Mupadolimab Biosimilar - Research Grade

Human

CD73

>1mg/ml

Human IgG1 (N297Q/E356D/M358L)-Kappa

Anti-Mouse CD73 (TY/23) In Vivo Antibody - Low Endotoxin (ICH1231), Oleclumab Biosimilar - Research Grade (ICH5038), Uliledlimab Biosimilar - Research Grade (ICH5131), Ansipastobart Biosimilar - Research Grade (ICH5349), Dresbuxelimab Biosimilar - Research Grade (ICH5490), Uprevstobart Biosimilar - Research Grade (ICH5960)

https://www.imgt.org/mAb-DB/

ICH3002

P21589

Blue ice

ICH5136 is a research-grade, unconjugated recombinant analog of mupadolimab (CPI-006), an antibody directed against human CD73 (5'-ectonucleotidase, NT5E; UniProt P21589). It is supplied for research use only as a non-therapeutic biosimilar built around the CD73 target — it is not the clinical drug and is not intended for human or veterinary use. The molecule is expressed as a human IgG1-kappa carrying engineered Fc substitutions (N297Q aglycosylation to reduce/ablate FcgammaR and complement engagement, plus E356D/M358L allotype residues), which makes it useful as a defined, Fc-silenced reagent for dissecting CD73-directed binding independent of effector function. Typical research applications include use as a positive control or capture/detection reagent in binding assays, as a tool for benchmarking anti-CD73 candidate antibodies, for epitope- and blocking-competition studies, for ADCC/ADC-development workflows, and in preclinical in-vitro model systems. It is offered at low endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg) and in bulk milligram-to-gram quantities to support assay development, screening, and scale-dependent workflows. Lot-appropriate QC (purity, binding) supports reproducible use. CD73 (ecto-5'-nucleotidase, encoded by NT5E; UniProt P21589) is a GPI-anchored, homodimeric cell-surface enzyme that catalyzes the dephosphorylation of extracellular AMP to adenosine. Working downstream of CD39 (which converts ATP/ADP to AMP), CD73 is the rate-limiting step of the adenosinergic axis, generating immunosuppressive extracellular adenosine that signals through P1 receptors (notably A2A/A2B) on immune cells. Adenosine dampens effector T-cell and NK-cell activity, promotes regulatory and myeloid suppressor populations, and supports an immunosuppressive, pro-angiogenic microenvironment. CD73 is broadly expressed on endothelium, epithelium, stromal cells, and subsets of lymphocytes, and is frequently upregulated in tumors, where high expression correlates with immune evasion. Beyond its catalytic role, CD73 contributes to cell adhesion and signaling. These properties make CD73 a prominent immuno-oncology target for antibodies and small-molecule inhibitors aiming to relieve adenosine-mediated immunosuppression.

5'-NT, 5'-deoxynucleotidase, Ecto-5'-nucleotidase, IMP-specific 5'-nucleotidase, Thymidylate 5'-phosphatase, 5'-nucleotidase, NT5E, NT5, NTE

Detects human CD73

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

N297Q

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.